IXICO and Cambridge Cluster Study to Detect Early Signs of Alzheimer's Disease
IXICO, Cambridge University, AstraZeneca and subsidiary MedImmune and Cambridge Cognition are jointly involved in a multimillion pound study to detect the early signs of Alzheimer's disease. Led by the University of Oxford, the teams will work with colleagues at 8 UK universities and the Alzheimer’s Society.
The Deep and Frequent Phenotyping study, which is being acclaimed as "the world’s most in depth probe in the space" 1, is being funded by the National Institute of Health Research and the MRC. The study has been designed to identify biomarkers to detect the occurrence of Alzheimer’s disease very early on in the progression of the disease, before any clinical manifestation.
The study will see extensive tests being performed on volunteers including up to 50 tests on 250 volunteers from the Dementia Platform UK (DPUK) cohorts. The tests include wearable devices, providing researchers with detailed information on volunteers movement and gait, and retinal imaging, observing subtle changes that affect a person’s central and peripheral vision.
1 and Source: http://www.businessweekly.co.uk/news/academia-research/cambridge-teams-alzheimer%E2%80%99s-diagnosis-study